Back to Search
Start Over
Impact of the ENHANCE trial on the use of ezetimibe in the United States and Canada.
- Source :
-
American heart journal [Am Heart J] 2014 May; Vol. 167 (5), pp. 683-9. Date of Electronic Publication: 2014 Feb 26. - Publication Year :
- 2014
-
Abstract
- Background: We previously found that the use of ezetimibe increased rapidly with different patterns between the United States (US) and Canada prior to the landmark Ezetimibe and Simvastatin in Hypercholesterolemia Enhance Atherosclerosis Regression (ENHANCE) trial, which was reported in January 2008, and failed to show that the drug slowed the progression of atherosclerosis. What is not known is how practice in the 2 countries changed after the ENHANCE trial. We examined ezetimibe use trends in the US and Canada before and after the reporting of the ENHANCE trial.<br />Methods: We conducted a population-based, retrospective, time-series analysis using the data collected by IMS Health in the US and CompuScript in Canada from January 1, 2002, to December 31, 2009. The main outcome measure was monthly number of prescriptions for ezetimibe-containing products.<br />Results: The monthly number of ezetimibe prescriptions/100,000 population rose from 6 to 1,082 in the US from November 2002 to January 2008, then significantly declined to 572/100,000 population by December 2009 after the release of the ENHANCE trial, a decrease of 47.1% (P < .001). In contrast, in Canada, use continuously rose from 2 to 495/100,000 population from June 2003 to December 2009 (P = .2). United States expenditures totaled $2.24 billion in 2009.<br />Conclusions: Ezetimibe remains commonly used in both the US and Canada. Ezetimibe use has decreased in the US post-ENHANCE, whereas use has gradually but steadily increased in Canada. The diverging patterns of ezetimibe use in the US and Canada require further investigation, as they reveal that a common evidence base is eliciting very different utilization patterns in neighboring countries.<br /> (Copyright © 2014 Mosby, Inc. All rights reserved.)
- Subjects :
- Anticholesteremic Agents administration & dosage
Anticholesteremic Agents economics
Atherosclerosis blood
Atherosclerosis epidemiology
Azetidines administration & dosage
Azetidines economics
Canada epidemiology
Cholesterol blood
Disease Progression
Dose-Response Relationship, Drug
Drug Costs
Drug Prescriptions statistics & numerical data
Ezetimibe
Follow-Up Studies
Humans
Hypercholesterolemia blood
Hypercholesterolemia complications
Prevalence
Retrospective Studies
Time Factors
Treatment Outcome
United States epidemiology
Atherosclerosis prevention & control
Azetidines therapeutic use
Hypercholesterolemia drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1097-6744
- Volume :
- 167
- Issue :
- 5
- Database :
- MEDLINE
- Journal :
- American heart journal
- Publication Type :
- Academic Journal
- Accession number :
- 24766978
- Full Text :
- https://doi.org/10.1016/j.ahj.2014.01.014